About SOLENO THERAPEUTICS INC

SOLENO THERAPEUTICS INC

Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program.

News Releases

Soleno Therapeutics Announces Peer-Reviewed Publication Of Data Comparing Dccr Treatment To The Natural History Of Prader-Willi Syndrome

_↗ investors.soleno.life

Apr 30, 2024

Soleno Therapeutics Receives Breakthrough Therapy Designation From U.S. Fda For Dccr (Diazoxide Choline) Extended-Release Tablets In Prader-Willi Syndrome (Pws)

_↗ investors.soleno.life

Apr 29, 2024

Soleno Therapeutics Announces Positive Statistically Significant Top-Line Results From Randomized Withdrawal Period Of Study C602 Of Dccr For Prader-Willi Syndrome

_↗ investors.soleno.life

Sep 26, 2023

Soleno Therapeutics Completes Enrollment In Randomized Withdrawal Period Of Study C602 Of Dccr For Prader-Willi Syndrome

_↗ investors.soleno.life

May 3, 2023

Disclaimer : All logos and trademarks on this website are the property of their respective owners. The information on this website is not a medical or investment related advice. The information about the company might not reflect the most current or accurate information. Please refer to the company's respective website for the most accurate information.